
Preliminary exploration of 17 α-hydroxyprogesterone cut-off value for neonatal congenital adrenal hyperplasia screening using a genetic screening processor in Sichuan region of China
Yang Lijuan, Zhou Jingyao, Ou Mingcai, Luo Zeming, Zhang Yu, Hu Qi, Chen Xuelian, Yang Yunxia
Preliminary exploration of 17 α-hydroxyprogesterone cut-off value for neonatal congenital adrenal hyperplasia screening using a genetic screening processor in Sichuan region of China
Objective To investigate the cut-off value of 17 α-hydroxyprogesterone(17α-OHP) level in neonatal dried blood spots for congenital adrenal hyperplasia(CAH) screening by using a genetic screening processor(GSP) at Sichuan Neonatal Disease Screening Center. Methods The time-resolved fluorescence method was used to measure the concentration of 17α-OHP in the dried blood spots on neonatal heel blood filter paper of 45423 neonates,and a retrospective analysis was performed for the correlation of gestational age and birth weight with 17α-OHP level in neonates. The percentile method was used to analyze the screening results,and the cut-off value was determined at P99.5. Results The r coefficient between gestational age and 17α-OHP value is -0.30, showing a negative correlation.The r coefficient between birth weight and 17α-OHP value is -0.17,and its absolute value is less than 0.3,indicating no correlation. The M(Q1,Q3) and 99.5th percentile of 17α-OHP level in preterm infants were significantly higher than those in full-term infants(Z=-52.52,P=0.000),and the M(Q1,Q3) and 99.5th percentile of 17α-OHP level in low-weight infants were significantly higher than those in infants with normal weight(Z=-36.45,P=0.000). Conclusion It is recommended to adjust the cut-off value of 17α-OHP based on gestational age for neonates in Sichuan region and modify the cut-off value of 17α-OHP screening as 28.5 nmol/L for preterm infants and 13.0 nmol/L for full-term infants.
congenital adrenal hyperplasia / gestational age / 17 α-hydroxyprogesterone / cut-off value
1 |
|
2 |
|
3 |
|
4 |
|
5 |
|
6 |
国家卫生健康委临床检验中心新生儿遗传代谢病筛查室间质评委员会. 新生儿先天性肾上腺皮质增生症筛查与诊断实验室检测技术专家共识[J]. 中华检验医学杂志,2019,42(12):1014-1019.
The Quality Evaluation Committee for the Screening of Genetic Metabolic Diseases in Newborns at the Clinical Laboratory Center of the National Health Commission. Expert consensus on laboratory detection technology for screening and diagnosis of neonatal congenital adrenal hyperplasia[J]. Chin J Lab Med,2019,42(12):1014-1019.
|
7 |
|
8 |
张 虹,袁 帅. 宿迁地区先天性肾上腺皮质增生症筛查结果的探讨分析[J]. 临床检验杂志(电子版),2020,9(3):362-364.
|
9 |
龙琪琛,张天娇,赵海建,等. 重视17α-羟孕酮的准确测定并加快推进其标准化进程[J]. 中华检验医学杂志,2020,43(12):1172-1180.
|
10 |
|
11 |
|
12 |
|
13 |
|
14 |
|
15 |
中华预防医学会出生缺陷预防与控制专业委员会新生儿筛查学组,中国医师协会青春期医学专业委员会临床遗传学组,中华医学会儿科学分会内分泌遗传代谢学组. 先天性肾上腺皮质增生症新生儿筛查共识[J]. 中华儿科杂志,2016,54(6):404-409.
Newborn Screening Group of the Birth Defects Prevention and Control Professional Committee of the Chinese Association of Preventive Medicine. Consensus of neonatal screening for congenital adrenal hyperplasia[J]. Chin J Pediatr,2016,54(6):404-409.
|
16 |
中华医学会儿科分会罕见病学组,中国医师协会医学遗传医师分会,中国妇幼保健协会出生缺陷防治与分子遗传分会,等. 21羟化酶缺陷导致的先天性肾上腺皮质增生症的实验室诊断共识[J] .中华医学遗传学杂志,2023,40(7):769-780.
Rare Diseases Group,Pediatric Branch of Chinese Medical Association; Medical Geneticists Branch of Chinese Medical Doctor Association; Birth Defect Prevention and Molecular Genetics Branch of China Maternal and Child Health Care Association,et al. Consensus on the laboratory diagnosis of congenital adrenal hyperplasia due to 21 hydroxylase deficiency[J]. Chin J Med Genet,2023,40(7):769-780.
|
17 |
韩连书,田国力,王维鹏. 新生儿遗传代谢病筛查指标切值建立方法专家共识[J]. 中国实用儿科杂志,2019,34(11):881-884.
|
18 |
中华预防医学会出生缺陷预防与控制专业委员会新生儿遗传代谢病筛查学组. 新生儿筛查遗传代谢病诊治规范专家共识[J]. 中华新生儿科杂志(中英文),2023,38(7):385-394.
Screening Group of Neonatal Genetic Metabolic Disease,Special Committee of Birth Defects Prevention and Control,Chinese Preventive Medical Association. Consensus on diagnosis and treatment of inherited metabolic diseases by newborn screening[J]. Chin J Neonatol,2023,38(7):385-394.
|
/
〈 |
|
〉 |